Result of General Meeting

RNS Number : 4653F

Cambridge Cognition Holdings PLC

09 March 2020

 

Cambridge Cognition Holdings Plc

(" Cambridge Cognition"   or the "Company")

Result of General Meeting

Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, is pleased to announce that all of the Resolutions proposed at the General Meeting held at its offices today to approve the proposed Placing and Subscription of up to 7,000,000 New Ordinary Shares and other related matters were duly passed.

Full details of the Resolutions were set out in the Circular published by the Company on 19 February 2020. The Circular is available for inspection in electronic form on the Company's website, www.cambridgecognititon.com .

Total Voting Rights

Further to Admission, the Company's issued Ordinary Share capital will consist of 31,170,093 Ordinary Shares of 1 pence each, with voting rights. The Company does not hold any shares in Treasury.

Therefore the total number of voting rights is 31,170,093 and this figure may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Defined terms used in this announcement have the meanings ascribed to them in the circular to shareholders dated 19 February 2020 unless otherwise defined.

Enquiries

Cambridge Cognition Holdings PLC Matthew Stork, Chief Executive Officer Nick Walters, Chief Financial Officer	Tel: [phone] [e-mail]
finnCap Ltd (NOMAD and Joint Broker) Geoff Nash / Simon Hicks / Teddy Whiley Alice Lane/Manasa Patil	Tel: [phone] (Corporate Finance) (ECM)
Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant	Tel: [phone]
IFC Advisory Ltd (Financial PR and IR) Tim Metcalfe / Graham Herring / Zach Cohen	Tel: [phone]

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

END

 

 

ROMFLFSFVIIAIII